MAPT and Alzheimer disease: To demonstrate how the IMD may be used to rapidly measure such drug effects in the live brain, we performed a case study measuring drug response phenotypes to 12 pharmacological agents across two murine models of AD, a transgenic (TG) htau hemizygous for TG MAPT expression multiple tau isoforms, and non-carrier (non-TG).